Wegovy Weight Loss Tablets: What You Need to Decide Before Starting

Is the tablet format right for you, or does the injection make more sense?

This is the first real decision most people face. The Wegovy injection (once weekly) and the Wegovy tablet (once daily) both deliver semaglutide, but they do so in meaningfully different ways, and that affects how you live with the treatment.

The tablet has one firm daily requirement: you take it first thing in the morning, on an empty stomach, with a small amount of plain water (roughly up to 120 ml). Then you wait at least 30 minutes before eating, drinking coffee, or taking any other oral medicines. Semaglutide is not well absorbed if those conditions aren't met, so the routine matters. Think of it like setting the kettle to boil and getting your tablet in before anything else.

If that structure suits how your mornings already run, the tablet can fit in easily. If your mornings are unpredictable (shift work, young children, irregular eating times) the injection's once-weekly timing may actually be simpler to manage in practice. There is no universally correct answer; it depends on your daily life. Oral Wegovy for weight loss covers this comparison in more depth if you want to think it through further.

Storage is one clear advantage of the tablet. Unlike the pen, there is no need to keep it in the fridge. The tablets store at room temperature, which matters if your fridge space is limited or you travel frequently.

What the evidence actually shows for weight loss tablets wegovy

The OASIS 4 phase-3 trial is the primary evidence base for Wegovy tablets. It enrolled 307 adults living with obesity or overweight plus at least one weight-related condition, ran for 64 weeks, and compared the 25 mg oral semaglutide schedule against a placebo, both groups alongside lifestyle support.

Average weight loss across all participants on the tablet was around 13.6%, compared with about 2.4% on placebo. Among those who adhered fully to the treatment schedule, the average reached close to 17%. That second figure is the one sometimes quoted in headlines; it is accurate, but only for fully adherent participants, not the trial group as a whole. Both figures come from Novo Nordisk's published data at the time of MHRA approval.

For context, the Wegovy injection at its 2.4 mg maintenance dose averaged roughly 15% weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The 7.2 mg injection dose, approved by the MHRA in early 2026, narrows the gap further. So the tablet sits meaningfully between the standard injection dose and the higher 7.2 mg option in terms of average outcomes, though individual results vary, and a clinical trial average is not a personal prediction.

The most common side effects in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation affected a substantial proportion of participants on the active tablet. These effects were mostly mild to moderate and tended to ease as the body adjusted. You can read more about the semaglutide side-effect profile on the NHS semaglutide medicines page, which covers both the injection and oral formulations.

Who can be prescribed Wegovy tablets, and what the NHS position is right now

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. The tablet is taken alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.

A lower BMI threshold can apply for certain ethnic backgrounds under UK clinical guidance; a prescriber will take this into account during assessment. BMI alone never confirms suitability. Wegovy tablets are not recommended during pregnancy, for anyone breastfeeding, or for those trying to conceive. They are not licensed for use in under-18s. People with a history of certain thyroid or pancreatic conditions will need careful prescriber review before starting.

On the NHS, Wegovy tablets are not currently available. A NICE appraisal would need to follow the MHRA approval before NHS commissioning could begin, and that process takes time. Right now, the tablet is available only via private prescription. If you want to explore your options, the weight-loss treatments page explains how the private assessment process at nume works. Our clinical team reviews every consultation personally, no automated decisions.

It is also worth knowing that Rybelsus, another oral semaglutide tablet, is licensed for type 2 diabetes at different strengths (3 mg, 7 mg and 14 mg). Those are not Wegovy tablet doses. The Wegovy weight loss pills page sets out the full dosing schedule (1.5 mg, 4 mg, 9 mg, 25 mg) and explains how the tablet differs from Rybelsus, so there is no confusion between the two products. If you come across references to semaglutide 7 mg tablets, that page explains the Rybelsus distinction clearly so there is no confusion between the two products.

What to think about before you consult a prescriber

The practical questions worth having clear in your mind before a consultation are simpler than people expect. Can you reliably take a tablet first thing every morning, at least 30 minutes before food or drink? Do you have a weight-related condition that affects your day-to-day health? Have you tried lifestyle changes and found them insufficient on their own?

You do not need a GP referral to access Wegovy tablets privately, and there is no waiting list. Equally, a prescriber may decide another treatment suits you better (the Wegovy injection, or tirzepatide) and that conversation is part of the consultation, not a hurdle to pass. If you want to understand how semaglutide tablets for weight loss compare with other options before speaking to someone, that page lays out the landscape. The Wegovy pill overview covers the full clinical picture for anyone who wants more detail on the approval and mechanism before deciding.

A private prescription for Wegovy tablets from a regulated UK pharmacy includes clinical assessment, dispensing, and any follow-up support. The guide to buying semaglutide tablets in the UK explains how to verify any online pharmacy on the GPhC register and what to look for in a legitimate service. Pricing for private weight-loss treatments varies; the contextual detail on what these medicines typically cost privately, and what a legitimate prescription includes, is on the weight loss treatments page.

If you have questions about the process, the FAQs page covers the most common ones, and the contact page connects you with the aftercare team seven days a week. When you are ready, you can start your free consultation and have your answers reviewed the same day by a GPhC-registered prescriber.